Business, energy, technology, markets and global industry news from Business News Today

evorpacept

PharmaDeviceNews evorpacept
Representative image: Gastric cancer imaging and biomarker analysis illustrate ALX Oncology’s evorpacept results in HER2-positive, CD47-high tumors from the ASPEN-06 study.
Pharma & Biotech

Evorpacept biomarker signal deepens in HER2-positive gastric cancer as ALX Oncology shifts focus

ALX Oncology’s evorpacept raises response to 63.6% in a HER2-retained, CD47-high gastric cancer subgroup, supporting biomarker-led development.

Read More
Representative image: ALX Oncology’s evorpacept update highlights how CD47-high biomarker data and HER2-positive metastatic breast cancer trial design could shape the next phase of oncology drug development.
Pharma & Biotech

Why ALX Oncology’s ASPEN-09 readout may matter beyond one HER2 breast cancer study

ALX Oncology has a CD47 signal. The harder test is whether ASPEN-09 can turn a tiny responder cohort into Phase 2 confidence.

Read More
Pharma & Biotech

What ALX Oncology’s new CD47 findings suggest about biomarker-driven immuno-oncology strategies

Discover how ALX Oncology’s CD47 biomarker data could reshape immuno-oncology strategies and what risks still stand for evorpacept.

Read More